Home
This site is intended for healthcare professionals
Advertisement

South London NHS Health Checks Filter Pathway

Share
Advertisement
Advertisement
 
 
 

Description

NHS Health Check Training

Delivered by Michaela Nuttall RGN MSc

Former Clinical Advisor Personalised Prevention OHID

Chair Health Care Committee HEART UK

This is a Face to Face event, this bespoke NHS Health Check Training is a great opportunity to update your knowledge nationally and locally, whilst networking with colleagues from across Bromley.

This event is for Bromley only, please visit the Smart Health Solutions website for more information on the NHS Health Check training.

This course will provide the learner with updated knowledge and understanding to support them in carrying out an NHS Health Check assessment and to inform the client of the significance of their results and their risk, providing brief advice if required.

It provides underpinning knowledge for the core competences and technical competences described in the NHS Health Check competence framework produced by Public Health England.

Learning Outcomes

  • State why NHS Health Checks are important.
  • Identify non-modifiable risk factors for cardiovascular disease.
  • Identify modifiable risk factors for cardiovascular disease.
  • Know the NHS Health Check filters
  • State how an NHS Health Check should be conducted.
  • Identify how an NHS Health Check can assess and interpret the risk of cardiovascular disease.
  • State how the risk of cardiovascular disease and opportunities for reducing this risk may best be communicated

Who should attend

Anyone involved in the delivery of health checks including:

  • Practice Nurses
  • Nurse Practitioners
  • GPs
  • Health Care Assistants
  • Care co-ordinators
  • Social Prescribers
  • Administration
  • Practice Staff
  • Pharmacists
  • Allied Healthcare Professionals
  • Health Trainers & Champions
  • Healthy Lifestyle Professionals

Certificates of participation are available to all attendees on submission of evaluation and handouts for each course are available for future reference via the MedAll platform.

We are a registered Centre for the Royal Society of Public Health (RSPH), and HEART UK supports our cardiovascular training. The NHS Health Check Competency Framework underpins our training.

We are proud of our strong heritage in supporting the NHS Health Check Programme, especially for training we have been providing since 2008 and that we have won all training tenders we have bid for.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

South London NHS Health Check Diabetes Filter Pathway Filter criteria: Age 40-74 and BP: Systolic ≥ 140mmHg and/or Diastolic ≥ 90mmHg 2 Or BMI ≥ 30 kg/m 2 Or BMI ≥ 27.5 kg/m (South Asian/Chinese) Perform HbA1c (+FBC ) Exclusions Perform HbA1c – Point of Care Testing * Exclusions 1 apply (venous blood sample) If HbA1c ≥ 42mmol/mol (6.0%) Repeat HbA1c (+FBC ) (venous blood sample) Exclusions apply 1 HbA1c HbA1c ≥ 48mmol/mol (6.5%) HbA1c Type 2 diabetes very likely ≥ 42mmol/mol but <48mmol/mol ≥ 37mmol/mol (5.5%) < 42mmol/mol (6.0%) (≥6.0% but< 6.5%) Moderate risk of diabetes High risk of Type 2 Diabetes 3 (non-diabetic hyperglycaemia) Offer brief intervention: If symptoms If no symptoms 1. Discuss risk of developing diabetes Refer same day 2. Help modify individual risk factors (immediately if Retest within 3. Offer tailored support services necessary)to GP 4 weeks Retest at next NHS Health Check (or every 3 years if additional risk factors for diabetes) HbA1c HbA1c ≥ 48mmol/mol <48mmol/mol (6.5%) (6.5%) HbA1c <37mmol/mol (5%) Diagnosis Offer an intensive lifestyle programme Low risk of diabetes Offer brief intervention: Type 2 1. Risk of developing diabetes Diabetes 1 2. Benefits of a healthy lifestyle Exclusions apply 3. Modifying risk factors Retest HbA1c Retest at next NHS Health Check after 6 months (if any previous test ≥48mmol/mol) Or at least once a year (if ≥42 bu<48mmol/mol) (Or before if patient develops symptoms of diabete) Check Weight, BMI & BP at least once a year 4 120 minutes < 7.8 mmol/l If high suspicion of diabetes an OGTT may be performed (Should be considered as exceptional) High risk of Type 2 diabetes (presumed normal glucose regulation on OGTT but high HbA1c) Fasting BG >7.8 and/or Oral Glucose Tolerance Test Fasting < 7mmol/l and 120 minutes ≥ 11.1 mmol/mol (fasting BG, 75g oral glucose 120minutes <7.8 - <11.1 mmol/l then blood glucose 120minutes) Impaired Glucose Tolerance 1HbA1c should not be used to diagnose/exclude diabetes if: The patient has symptoms of less than 2 months duration, as an individual can be significantly hyperglycaemic without HbA1c having had sufficient time to rise. Fasting 6.1-6.9 mmol/l and If a patient is acutely unwell (for the same reasons as above) 120 minutes < 7.8 mmol/l Impaired Fasting Glycaemia In pregnancy. In patients aged 18 years or younger. In patients with suspected type 1 diabetes (e.g. presence of ketones) at any age. In patients taking medications that cause rapid glucose elevation (e.g. steroids & antipsychotic medications) Offer an intensive lifestyle In patients who have known genetic, haematological or illness-related factors that programme influence HbA1c and its measurement (see overleaf detailed guidance) In patients with known anaemia (Hb < 10.5g/dl) or taking iron supplement In the above circumstances, a random venous glucose sample must be checked (≥ 11.1mmol/l is diagnostic of diabetes in the presence of diabetes symptoms.) Check Weight, BMI, BP and HbA1c at least once a year 2If no Full Blood Count (FBC) record within last 12 months 3Symptoms: polyuria, polydipsia, unexplained weight loss. 4 If diabetes symptoms (as above) and/or multiple risk factors for *Relevant sites/ providers only: developing diabetes. 5Additional risk factors for diabetes: first-degree relative with diabetes, women using approved POCT equipment: who delivered baby weighting >4kgs or with diagnosis of Gestational Diabetes MellituAfinion, B-Analyst, Cobas B101, or with Polycystic Ovary Syndrome, severe obesity, acanthosis nigricans and is more DCA Vantage prevalent in people of South Asian, Chinese, African-Caribbean and black African descent.Factors that interfere with HbA1c test results: 1- Inherited hemoglobin variants (hemoglobinopathies) : 1 HbA1c test can be unreliable for diagnosing or monitoring diabetes and impaired glucose regulation. • HbS: African & South or Central America (especially Panama), Caribbean islands, Mediterranean countries (such as Turkey, Greece, and Italy), India, and Saudi Arabia. • HbC: West African descent. • HbE : Asian, especially those of Southeast Asian descent. Commonin Cambodia, Indonesia, Laos, Malaysia, Thailand, and Vietnam Also seen in southern China, India, the Philippines, and Turkey. HbSC: West African descent. Also found in East India, the Mediterranean, and the Middle East. Homozygous state: HbA1c test should not be used for patients with condition such as HbSS (sickle cell anemia), HbCC, HbEE or HbSC (sickled hemoglobin C disease). Even if an assay does not interfere with their variant, these patients may suffer anemia, increased red blood cell turnover and transfusionrequirements which 2 can adversely affect HbA1c results . 2- Factors that influence Hba1c and its measurement 3 • Erythropoiesis Increased HbA1c: iron, vitamin B12 deficiency, decreased erythropoiesis. Decreased HbA1c: administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease. • Altered Haemoglobin Genetic or chemical alterations in haemoglobin: haemoglobinopathies, HbF, methaemoglobin, may increase or decrease HbA1c. • Glycation Increased HbA1c: alcoholism, chronic renal failure, decreased intraerythrocyte pH. Decreased HbA1c: aspirin, vitamin C and E, certain haemoglobinopathies, increased intra-erythrocyte pH. Variable HbA1c: genetic determinants. • Erythrocyte destruction Increased HbA1c: increased erythrocyte life span: Splenectomy. Decreased A1c: decreased erythrocyte life span: haemoglobinopathies, splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin and dapsone. • Assays Increased HbA1c: hyperbilirubinaemia, carbamylated haemoglobin, alcoholism, large doses of aspirin, chronic opiate use. Variable HbA1c: haemoglobinopathies. Decreased HbA1c: hypertriglyceridaemia. 3- Practical recommendations: The relevance of above considerationsare “invisible” in certain of the available assays. An updated list on effects of frequentlyencountered Hb variants and derivatives on HbA1c measurementscan be found at: http://www.ngsp.org/factors.asp Assays used locally: • GSTT & King’s: Menarini H8040 column chromatography, not affectedby Hb variants. Anaemia: only if significant <10g/L for a noticeable effect on result. • Lewisham & Greenwich: Biorad Turbo ion exchange chromatography, affectedby some variants but able to detect short red cell life span. PRUH: HPLC method (Biorad) which is not affected by Hb variants. • NPT Afinion: boronate affinity separation, not affected by variants except HbF . - A FBC is recommended if Hb variant status unknown or uncertain or clinically suspected anaemia (e.g. elderly, menorrhagia) or no Hb record in preceding 12 months. 1 SickleCell trait and other hemoglobinopathiesand diabetes: important information for providers, National Diabetes Information Clearinghouse, availableat http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/index.aspx 2 Factors that Interfere with HbA1c test results, National Glycohemoglobin Standardization Program, availableat http://www.ngsp.org/factors.asp 3 Use of Glycated heamoglobin(HbA1c) in the diagnosis of diabetes Mellitus, abbreviated report of a WHOconsultation, 2011, availableat http://www.who.int/diabetes/publications/en/ 4 Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria, E. lenters- Westra & R. J. Slingerland, ClinicalChemistry, 1062-1072 (2014) Reviewed and updated: March 2015 South London Cardiovascular Prevention Group